Christopher Bowlus

Christopher Bowlus is affiliated with the Department of Internal Medicine at Yale School of Medicine, where he contributes to research in hepatology and gastroenterology. His work primarily focuses on autoimmune and cholestatic liver diseases, particularly primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

His research interests include the clinical evaluation of novel therapeutics such as seladelpar and elafibranor, with a focus on long-term safety, efficacy, and biomarker analysis. He investigates racial and ethnic disparities in disease presentation, pruritus management, and treatment outcomes in chronic liver conditions.

The recent publications highlight a strong trend in clinical trials and longitudinal studies assessing PPAR agonists and other targeted therapies. These studies examine both biochemical markers (e.g., alkaline phosphatase) and patient-reported outcomes (e.g., pruritus), contributing significantly to the understanding and treatment of cholestatic liver diseases.

Christopher Bowlus collaborates with leading researchers across institutions and is actively involved in multi-center trials and consortium-based research, as evidenced by his frequent co-authorship on studies involving large patient cohorts and registry data.

He has no listed scientific awards in the provided text.

There is no information available regarding student mentorship, grant funding, or teaching responsibilities. His role appears to be research-focused, likely within a clinical or translational framework.

He is associated with research teams investigating liver fibrosis, cholestasis, and autoimmune mechanisms in liver disease, often collaborating through consortia such as the Consortium for Autoimmune Liver Disease.